NasdaqGS:UTHRBiotechs
A Look At United Therapeutics (UTHR) Valuation After Positive TETON-1 IPF Phase 3 Results
Why the TETON-1 IPF data matters for United Therapeutics (UTHR)
United Therapeutics (UTHR) just reported positive Phase 3 TETON-1 results for nebulized Tyvaso in idiopathic pulmonary fibrosis, with meaningful lung function gains, fewer clinical worsening events, and no new safety concerns.
The company now plans to seek FDA priority review to add IPF to Tyvaso’s label. This would target a large, underserved patient group and has quickly sharpened investor focus on UTHR’s growth story.
See our...